Bionano Genomics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen initiated coverage of Bionano Genomics (BNGO) with a Buy rating and $10 price target Bionano is a commercial-stage life science tools company marketing instruments and consumables for genome analysis using optical genome mapping technology, the analyst tells investors in a research note. The firm says the company has a growing business in genome analysis solutions “valued at less than 1/10 of industry’s average valuation multiple.”